HC Wainwright & Co. Maintains Neutral on Virios Therapeutics, Lowers Price Target to $0.2
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Sean Lee maintains a Neutral rating on Virios Therapeutics (NASDAQ:VIRI) and lowers the price target from $0.4 to $0.2.
August 09, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. analyst Sean Lee maintains a Neutral rating on Virios Therapeutics and lowers the price target from $0.4 to $0.2.
The lowered price target from $0.4 to $0.2 by HC Wainwright & Co. suggests a negative outlook on Virios Therapeutics' stock performance. This is likely to put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100